Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome
Anavex received FDA clearance of its IND for blarcamesine in Fragile X syndrome, an indication with no FDA-approved treatment. The IND is now open, giving Anavex open INDs across all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome.
Key figures
- Drug Name
- ANAVEX®2-73 (blarcamesine)
- Phase Of Trial
- Phase 2a
- Study design
- randomized, double-blind, placebo-controlled, dose-ranging
- Planned subjects
- approximately 60 adult males with FXS
- Us prevalence range
- 38,000 to 87,000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.